Discovery of Carbonic Anhydrase 9 as a Novel CLEC2 Ligand in a Cellular Interactome Screen
Cells · 2024
DOI: 10.3390/cells13242083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Sebastian Hoffmann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany. Hauptthemen laut MEDLINE: Lectins, C-Type, Protein Binding, Carbonic Anhydrase IX. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Abstract (Originalsprache)
Membrane proteins, especially extracellular domains, are key therapeutic targets due to their role in cell communication and associations. Yet, their functions and interactions often remain unclear. This study presents a general method to discover interactions of membrane proteins with immune cells and subsequently to deorphanize their respective receptors. We developed a comprehensive recombinant protein library of extracellular domains of human transmembrane proteins and proteins found in the ER-Golgi-lysosomal systems. Using this library, we conducted a flow-cytometric screen that identified several cell surface binding events, including an interaction between carbonic anhydrase 9 (CAH9/CA9/CAIX) and CD14high cells. Further analysis revealed this interaction was indirect and mediated via platelets bound to the monocytes. CA9, best known for its diverse roles in cancer, is a promising therapeutic target. We utilized our library to develop an AlphaLISA high-throughput screening assay, identifying CLEC2 as one robust CA9 binding partner. A five-amino-acid sequence (EDLPT) in CA9, identical to a CLEC2 binding domain in Podoplanin (PDPN), was found to be essential for this interaction. Like PDPN, CA9-induced CLEC2 signaling is mediated via Syk. A Hodgkin’s lymphoma cell line (HDLM-2) endogenously expressing CA9 can activate Syk-dependent CLEC2 signaling, providing enticing evidence for a novel function of CA9 in hematological cancers. In conclusion, we identified numerous interactions with monocytes and platelets and validated one, CA9, as an endogenous CLEC2 ligand. We provide a new list of other putative CA9 interaction partners and uncovered CA9-induced CLEC2 activation, providing new insights for CA9-based therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Immunology and Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
- Division of High-Throughput Biology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
- Division of Biotherapeutics Discovery, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
ORCID-Profile: Sebastian Hoffmann, Benedict-Tilman Berger, John Edward Park
Förderung
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
Zitieren
APA
Hoffmann, S., Berger, B. T., Lucas, L. R., Schiele, F., & Park, J. E. (2024). Discovery of Carbonic Anhydrase 9 as a Novel CLEC2 Ligand in a Cellular Interactome Screen. Cells. https://doi.org/10.3390/cells13242083
Vancouver
Hoffmann S, Berger BT, Lucas LR, Schiele F, Park JE. Discovery of Carbonic Anhydrase 9 as a Novel CLEC2 Ligand in a Cellular Interactome Screen. Cells. 2024. doi:10.3390/cells13242083
BibTeX
@article{Hoffmann2024,
author = {Hoffmann, Sebastian and Berger, Benedict-Tilman and Lucas, Liane Rosalie and Schiele, Felix and Park, John Edward},
title = {Discovery of Carbonic Anhydrase 9 as a Novel CLEC2 Ligand in a Cellular Interactome Screen},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13242083}
}
EUVIMED